Ind-Swift Laboratories Limited (INDSWFTLAB.BO)
INR 86.38
(3.37%)
INR 86.38
(3.37%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 12.8 Billion INR | 6.1% |
| 2022 | 12.07 Billion INR | 16.23% |
| 2021 | 10.38 Billion INR | 16.54% |
| 2020 | 8.91 Billion INR | 14.33% |
| 2019 | 7.79 Billion INR | 3.05% |
| 2018 | 7.56 Billion INR | -0.78% |
| 2017 | 7.62 Billion INR | 6.46% |
| 2016 | 7.16 Billion INR | 9.64% |
| 2015 | 6.53 Billion INR | -1.09% |
| 2014 | 6.6 Billion INR | -31.57% |
| 2013 | 9.65 Billion INR | -15.05% |
| 2012 | 11.36 Billion INR | -19.38% |
| 2011 | 14.09 Billion INR | 35.88% |
| 2010 | 10.37 Billion INR | 32.06% |
| 2009 | 7.85 Billion INR | 33.06% |
| 2008 | 5.9 Billion INR | 28.93% |
| 2007 | 4.57 Billion INR | 30.7% |
| 2006 | 3.5 Billion INR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 331.66 Million INR | -91.57% |
| 2023 Q1 | 3.1 Billion INR | 2.0% |
| 2023 FY | 12.8 Billion INR | 6.1% |
| 2023 Q4 | 3.93 Billion INR | 36.81% |
| 2023 Q3 | 2.87 Billion INR | -0.76% |
| 2023 Q2 | 2.89 Billion INR | -6.65% |
| 2022 Q1 | 2.8 Billion INR | -8.63% |
| 2022 FY | 12.07 Billion INR | 16.23% |
| 2022 Q4 | 3.04 Billion INR | -2.7% |
| 2022 Q3 | 3.12 Billion INR | 0.8% |
| 2022 Q2 | 3.1 Billion INR | 10.72% |
| 2021 Q1 | 2.49 Billion INR | 10.26% |
| 2021 Q4 | 3.06 Billion INR | 24.33% |
| 2021 Q3 | 2.46 Billion INR | 4.67% |
| 2021 Q2 | 2.35 Billion INR | -5.67% |
| 2021 FY | 10.38 Billion INR | 16.54% |
| 2020 FY | 8.91 Billion INR | 14.33% |
| 2020 Q2 | 2.28 Billion INR | 8.56% |
| 2020 Q3 | 2.26 Billion INR | -0.88% |
| 2020 Q4 | 2.26 Billion INR | 0.13% |
| 2020 Q1 | 2.1 Billion INR | 6.88% |
| 2019 Q4 | 1.96 Billion INR | -3.43% |
| 2019 FY | 7.79 Billion INR | 3.05% |
| 2019 Q3 | 2.03 Billion INR | 6.34% |
| 2019 Q2 | 1.91 Billion INR | 2.12% |
| 2019 Q1 | 1.87 Billion INR | -6.56% |
| 2018 Q2 | 1.67 Billion INR | -9.68% |
| 2018 FY | 7.56 Billion INR | -0.78% |
| 2018 Q4 | 2 Billion INR | 1.15% |
| 2018 Q1 | 1.85 Billion INR | 0.0% |
| 2018 Q3 | 1.98 Billion INR | 18.72% |
| 2017 FY | 7.62 Billion INR | 6.46% |
| 2016 FY | 7.16 Billion INR | 9.64% |
| 2015 FY | 6.53 Billion INR | -1.09% |
| 2014 FY | 6.6 Billion INR | -31.57% |
| 2013 FY | 9.65 Billion INR | -15.05% |
| 2012 Q2 | 3.27 Billion INR | 8.34% |
| 2012 FY | 11.36 Billion INR | -19.38% |
| 2012 Q3 | 2.32 Billion INR | -29.1% |
| 2012 Q1 | 3.02 Billion INR | 0.0% |
| 2012 Q4 | 2.72 Billion INR | 17.37% |
| 2011 FY | 14.09 Billion INR | 35.88% |
| 2010 FY | 10.37 Billion INR | 32.06% |
| 2009 FY | 7.85 Billion INR | 33.06% |
| 2008 FY | 5.9 Billion INR | 28.93% |
| 2007 FY | 4.57 Billion INR | 30.7% |
| 2006 FY | 3.5 Billion INR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Bajaj HealthCare Limited | 4.73 Billion INR | -170.564% |
| Glenmark Life Sciences Limited | 22.83 Billion INR | 43.899% |
| Hester Biosciences Limited | 3.04 Billion INR | -320.593% |
| Lupin Limited | 200.1 Billion INR | 93.599% |
| Medicamen Biotech Limited | 1.79 Billion INR | -614.365% |
| Medico Remedies Limited | 1.44 Billion INR | -783.863% |
| NATCO Pharma Limited | 40.02 Billion INR | 67.994% |
| Achyut Healthcare Limited | 61.36 Million INR | -20772.1% |
| Ajanta Pharma Limited | 42.08 Billion INR | 69.565% |
| Alkem Laboratories Limited | 126.67 Billion INR | 89.888% |
| Alpa Laboratories Limited | 1.08 Billion INR | -1077.958% |
| Alembic Pharmaceuticals Limited | 61.12 Billion INR | 79.043% |
| AstraZeneca Pharma India Limited | 12.95 Billion INR | 1.129% |
| Aurobindo Pharma Limited | 287.04 Billion INR | 95.538% |
| Brooks Laboratories Limited | 794.86 Million INR | -1511.477% |
| Divi's Laboratories Limited | 78.45 Billion INR | 83.672% |
| Dr. Reddy's Laboratories Limited | 279.16 Billion INR | 95.412% |
| Eris Lifesciences Limited | 20.09 Billion INR | 36.246% |
| FDC Limited | 19.42 Billion INR | 34.074% |
| Glenmark Pharmaceuticals Limited | 118.13 Billion INR | 89.157% |
| Granules India Limited | 45.06 Billion INR | 71.576% |
| Gufic Biosciences Limited | 8.06 Billion INR | -58.789% |
| Indoco Remedies Limited | 17.89 Billion INR | 28.419% |
| Ipca Laboratories Limited | 76.22 Billion INR | 83.196% |
| Jagsonpal Pharmaceuticals Limited | 2.08 Billion INR | -513.746% |
| Krebs Biochemicals & Industries Limited | 504.21 Million INR | -2440.384% |
| Lasa Supergenerics Limited | 1.04 Billion INR | -1127.68% |
| Laurus Labs Limited | 50.01 Billion INR | 74.391% |
| Mankind Pharma Limited | 103.34 Billion INR | 87.606% |
| Megasoft Limited | 373.95 Million INR | -3325.296% |
| Procter & Gamble Health Limited | 11.51 Billion INR | -11.261% |
| Piramal Pharma Limited | 81.71 Billion INR | 84.324% |
| RPG Life Sciences Limited | 5.82 Billion INR | -120.067% |
| Sigachi Industries Limited | 3.98 Billion INR | -221.063% |
| Sun Pharma Advanced Research Company Limited | 755.45 Million INR | -1595.539% |
| Sun Pharmaceutical Industries Limited | 484.96 Billion INR | 97.359% |
| Suven Pharmaceuticals Limited | 10.51 Billion INR | -21.833% |
| Syncom Formulations (India) Limited | 2.59 Billion INR | -394.09% |
| Unichem Laboratories Limited | 16.57 Billion INR | 22.717% |
| Windlas Biotech Limited | 6.3 Billion INR | -103.009% |
| ZIM Laboratories Limited | 3.67 Billion INR | -248.616% |
| Zydus Lifesciences Limited | 190.21 Billion INR | 93.266% |
| Bliss GVS Pharma Limited | 7.7 Billion INR | -66.298% |
| Wanbury Limited | 5.75 Billion INR | -122.514% |
| Amrutanjan Health Care Limited | 4.21 Billion INR | -204.085% |
| Bal Pharma Limited | 3.39 Billion INR | -277.602% |
| Strides Pharma Science Limited | 40.51 Billion INR | 68.382% |
| Venus Remedies Limited | 5.91 Billion INR | -116.57% |
| Aarti Pharmalabs Limited | 18.15 Billion INR | 29.447% |
| Nectar Lifesciences Limited | 16.84 Billion INR | 23.941% |
| Shilpa Medicare Limited | 11.51 Billion INR | -11.228% |
| Aarti Drugs Limited | 25.28 Billion INR | 49.343% |
| IOL Chemicals and Pharmaceuticals Limited | 21.18 Billion INR | 39.551% |
| Suven Life Sciences Limited | 116.92 Million INR | -10854.51% |
| Ind-Swift Limited | 5.02 Billion INR | -154.922% |
| Valiant Laboratories Limited | 1.82 Billion INR | -603.57% |
| J. B. Chemicals & Pharmaceuticals Limited | 34.84 Billion INR | 63.237% |
| Solara Active Pharma Sciences Limited | 12.38 Billion INR | -3.433% |
| Themis Medicare Limited | 3.81 Billion INR | -235.524% |
| Hikal Limited | 17.84 Billion INR | 28.225% |
| Torrent Pharmaceuticals Limited | 106.05 Billion INR | 87.922% |
| Sequent Scientific Limited | 13.69 Billion INR | 6.485% |
| Novartis India Limited | 3.35 Billion INR | -282.278% |
| Wockhardt Limited | 27.89 Billion INR | 54.073% |
| Jubilant Pharmova Limited | 67.02 Billion INR | 80.89% |
| Biofil Chemicals and Pharmaceuticals Limited | 400.35 Million INR | -3099.426% |
| Neuland Laboratories Limited | 15.58 Billion INR | 17.816% |
| Morepen Laboratories Limited | 17.01 Billion INR | 24.737% |
| Kilitch Drugs (India) Limited | 1.54 Billion INR | -729.746% |
| Mangalam Drugs & Organics Limited | 3.68 Billion INR | -247.509% |